The medical literature cited in the task force report
Transcripts and minutes of the three advisory committee meetings on the drug
FDA's Biopharmaceutic reviews of the NDA
We understand that physicians' and patients' names will not be disclosed to the public.
Kenneth F. King, Ph.D.
Vice President, Regulatory Affairs
Pharmacia & Upjohn Company
The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Appendix F: Upjohn Consent to Disclosure ."
Halcion: An Independent Assessment of Safety and Efficacy Data . Washington, DC: The National Academies Press,
Please select a format: